bioRxivCancer Biology
Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma
S. P. Caragher, J. M. Shireman, M. Huang, J. Miska, S. Baisiwala, C. Park, M. Saathoff, L. Warnke, T. Xiao, M. S. Lesniak, C. D. James, H. Meltzer, A. K. Tryba, A. U. Ahmed
Abstract
Glioblastoma (GBM) is one of the most aggressive and lethal tumor types. Evidence continues to accrue indicating that the complex relationship between GBM and the brain microenvironment contributes to this malignant phenotype. However, the interaction between GBM and neurotransmitters, signaling molecules involved in neuronal communication, remains incompletely understood. Here we examined, in both sexes of humans and mice, how the monoamine dopamine influences GBM cells. We demonstrate that GBM cells express DRD2, with elevated expression in the glioma-initiating cell (GIC) population. Stimulation of DRD2 caused neuron-like depolarization exclusively in GICs. In addition, long-term activation of DRD2 heightened the sphere-forming capacity of GBM cells as well as tumor engraftment efficiency. Mechanistic investigation revealed that DRD2 signaling activates the hypoxia response and functionally alters metabolism. Finally, we found that GBM cells synthesize and secrete dopamine themselves, suggesting a potential autocrine mechanism. These results identify dopamine signaling as a potential therapeutic target in GBM and further highlight neurotransmitters as a key feature of the pro-tumor microenvironment.\n\nSignificance StatementThis work offers critical insight into the role of the neurotransmitter dopamine in the progression of GBM. We show that dopamine induces specific changes in the state of tumor cells, augmenting their growth and shifting them to a more stem-cell like state. Further, we show that dopamine can alter the metabolic behavior of GBM cells, increasing glycolysis. Finally, we show that GBM cells, including tumor samples from patients, can synthesize and secrete dopamine, suggesting an autocrine signaling process underlying these results. These results describe a novel connection between neurotransmitters and brain cancer, further highlighting the critical influence of the brain milieu on GBM.
- organism: human
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: metabolism & bioenergetics
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- GABAergic neuron-to-glioma synapses in diffuse midline gliomas
Tara Barron, Belgin Yalçın, … Michelle Monje·NaturePeer-reviewed·Feb 19, 2025
- Synergistic Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma
Ling He, Kruttika Bhat, … Frank Pajonk·Radiotherapy and OncologyPeer-reviewed·Jun 5, 2021
- The Dopamine Receptor Antagonist TFP Prevents Phenotype Conversion and Improves Survival in Mouse Models of Glioblastoma
Kruttika Bhat, Mohammad Saki, … Frank Pajonk·Proceedings of the National Academy of SciencesPeer-reviewed·May 1, 2020
- Effects of Dopamine Receptor Antagonists and Radiation on Mouse Neural Stem/Progenitor Cells
Ling He, Kruttika Bhat, … Frank Pajonk·bioRxiv·Jan 18, 2023
- GABA production induced by imipridones is a targetable and imageable metabolic alteration in diffuse midline gliomas
Georgios Batsios, Suresh Udutha, … Pavithra Viswanath·bioRxiv·Jun 7, 2024
- Activation of the mevalonate pathway in response to anti-cancer treatments drives glioblastoma recurrences through activation of Rac-1
Ling He, Angeliki Diotima Ioannidis, … Frank Pajonk·Cancer Research CommunicationsPeer-reviewed·Jun 5, 2024